Mutations in the RNA-binding protein roquin-1 are known to result in humoral autoimmunity. Heissmeyer and colleagues show that MALT1 cleavage of roquin and regnase-1 downstream of TCR signaling releases cooperatively repressed targets to promote T H 17 cell differentiation
The digital transformation of healthcare is rapidly reshaping neurology, particularly in the field of movement disorders, where continuous monitoring, long disease trajectories, and complex multimodal care create a high demand for innovative solutions. Wearable sensors, digital diagnostics, app-based therapeutics, and integrated hybrid care networks and digital supported care pathways promise earlier diagnosis, personalized treatment and care management, and improved long-term outcomes. However, real-world implementation in managed outpatient care remains fragmented and faces major barriers beyond pure technological feasibility. This position paper critically reviews the current state of digital technologies in movement disorder care, identifies key systemic, ethical, and economic roadblocks, and proposes a pragmatic roadmap toward a realistic and ethically sound digital outpatient clinic. We argue that the future digital clinic will not be defined solely by technical progress, but by how consciously healthcare systems integrate digital tools to hybrid care solutions while preserving human-centered, equitable, and evidence-based care.
While the aetiology of Parkinson’s disease (PD) involves genetic and environmental factors, emerging evidence has suggested a surprising link between lipid metabolism - particularly serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) - and the pathogenesis of PD. Cholesterol plays a vital role in neuronal membrane integrity, myelination, and synaptic function. However, its peripheral concentration and regulatory mechanisms in the central nervous system (CNS), remain incompletely understood in the context of PD. This review aims to systematically examine the current literature on the relationship between TC and LDL-C with the risk and progression of PD in longitudinal patient cohorts. A systematic literature search was conducted using PubMed with the keywords “Parkinson’s disease” AND “cholesterol” and “Parkinson’s disease” AND “LDL.” Inclusion criteria encompassed English-language longitudinal human studies published before October 2024, with data on cholesterol levels in relation to PD incidence or progression. Fourteen studies met the eligibility criteria. Twelve of the 14 included studies reported an inverse association between lower serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels and increased risk for PD onset as well as faster disease progression. Notably, this pattern was not uniform across all subgroups: age, sex, BMI, and statin use modulated the strength and direction of associations. Despite some heterogeneity across studies, there is growing evidence that lower TC and LDL-C may be associated with a higher risk and more rapid progression of PD. Future research should focus on mechanistic studies and stratified analyses to clarify whether and how cholesterol modulation could contribute to neuroprotective strategies in PD.
To evaluate the effects of tiotropium/olodaterol (T/O) on phase-resolved functional lung (PREFUL) MRI parameters in hyperinflated chronic obstructive pulmonary disease (COPD) patients and examine correlations with conventional cardiopulmonary and hyperpolarized 129Xe MRI measures. Retrospective subanalysis of a prospective, randomized, placebo-controlled, crossover trial with open-label extension. Thirty-two patients with moderate-to-severe COPD (61.5 ± 7.7 years; 17 men); 30 completed the MRI extension at 1.5 T. PREFUL analysis yielded regional ventilation (RVent), flow-volume loop correlation metric (FVL-CM), normalized perfusion (QN), ventilation defect percentage (VDP), perfusion defect percentage (QDP), V/Q match metrics (VQM), and pulmonary pulse wave velocity (PWV; post-hoc parameter). Linear mixed-effects models tested treatment effects; correlations were evaluated with Spearman’s rank and bootstrap 95
Abstract Background Hypertrophic cardiomyopathy (HCM) is frequently associated with mutations in cardiac myosin binding protein C (cMyBP-C; MYBPC3) and cMyBP-C haploinsufficiency. Previously we discovered burst-like transcription of MYBPC3 and unequal amounts of wild type cMyBP-C from cardiomyocyte to cardiomyocyte in HCM-patient’s myocardium. The present study introduces human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) carrying the patient-specific heterozygous MYBPC3 c.927–2 A > G mutation and the respective isogenic control to examine in long-term culture whether comparable pathophysiological features exist in vitro. Methods We generated a human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) model harboring the patient-specific MYBPC3 c.927–2 A > G splice-site mutation. An isogenic control line was used for direct comparison. We assessed cMyBP-C protein expression, transcriptional dynamics, contractile function, and calcium handling, and compared the cellular phenotype to heart tissue from the HCM patient with the same mutation. Results cMyBP-C haploinsufficiency in MYBPC3 c.927–2 A> G -hiPSC-CMs was confirmed by Western blot. Immunostaining showed myofibrillar disarray and an increasing proportion of cMyBP-C-negative CMs over time for mutant hiPSC-CMs, closely mirrored the variable cMyBP-C protein expression observed in HCM-patient’s myocardium. RNA-FISH revealed variable MYBPC3 transcription from cell to cell, likely contributing to cMyBP-C expression heterogeneity. Twitch shortening velocity slowed over time while Ca²⁺ transient kinetics accelerated in mutant hiPSC-CMs. Transcriptomic analysis revealed dysregulation of pathways associated with contraction, calcium handling, and HCM. Conclusions This study presents a validated hiPSC-based model of MYBPC3-associated HCM that captures the variability in protein expression and functional phenotype observed in patient heart tissue. Our findings support the relevance of single-cell transcriptional variability in HCM pathogenesis and highlight the utility of this model for future studies.
